The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome.
Although less than 1% of patients with the antiphospholipid syndrome (APS) develop the catastrophic variant, its potentially lethal outcome emphasises its importance in clinical medicine today. However, the rarity of this variant makes it extraordinarily difficult to study in any systematic way. To put together all the published case reports as well as the new diagnosed cases from all over the world, an international registry of patients with catastrophic APS (CAPS Registry) was created in 2000 by the European Forum on Antiphospholipid Antibodies. Currently, it documents the entire clinical, laboratory and therapeutic data of more than 300 patients whose data has been fully registered. This registry can be freely consulted at the Internet (http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM), and it is expected that the periodical analysis of these data will allow us to increase our knowledge of this condition.
Bucciarelli
S
S
Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
Espinosa
G
G
Cervera
R
R
D016736:Antiphospholipid Syndrome / Q000145:classification / Q000150:complications / Q000401:mortality* / Q000628:therapy; D006801:Humans; D010951:Plasma Exchange; D011379:Prognosis; D012008:Recurrence; D012042:Registries; D013927:Thrombosis / Q000209:etiology